Smith & Nephew Q3 2024 Trading Report Filed

TL;DR

SNN dropped Q3 2024 trading update, check the press release for numbers.

AI Summary

Smith & Nephew plc announced its Third Quarter 2024 Trading Report on October 31, 2024. The report details the company's performance for the period ending September 30, 2024. Specific financial figures and operational highlights are expected to be within the press release referenced in the filing.

Why It Matters

This filing provides investors with an update on Smith & Nephew's recent financial and operational performance, crucial for assessing the company's trajectory and investment potential.

Risk Assessment

Risk Level: low — This is a routine quarterly trading update filing, not indicating any immediate or significant new risks.

Key Players & Entities

• SMITH & NEPHEW PLC (company) — Registrant
• October 31, 2024 (date) — Filing Date and Report Date
• 001-14978 (other) — SEC File Number

FAQ

Key Financial Figures

• $1,412 million — 24. Q3 Highlights 1,2 Q3 revenue of $1,412 million (Q3 2023: $1,357 million), representing
• $1,357 million — Q3 revenue of $1,412 million (Q3 2023: $1,357 million), representing 4.0% revenue growth (und
• $5.5 billion — ountries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent

Filing Documents

• tmb-20241031x6k.htm (6-K) — 342KB
• 0001558370-24-013993.txt ( ) — 343KB

Press release entitled " Smith+Nephew Third Quarter 2024 Trading Report ", dated October 31, 2024

Item 1. Press release entitled " Smith+Nephew Third Quarter 2024 Trading Report ", dated October 31, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Smith & Nephew plc (Registrant) Date: October 31, 2024 By: /s/ Helen Barraclough Helen Barraclough Company Secretary Smith+Nephew Third Quarter 2024 Trading Report 31 October 2024 Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the third quarter ended 28 September 2024. Q3 Highlights 1,2 Q3 revenue of $1,412 million (Q3 2023: $1,357 million), representing 4.0% revenue growth (underlying and reported) o Excluding China, Group growth was 5.9% (underlying and reported). China impacted by worse than expected headwinds across our surgical businesses o Operational and commercial improvements from 12-Point Plan on track across the rest of the business, with financial improvements coming through Orthopaedics revenue up 2.3% (2.4% reported), with US Hip and Knee Implants both delivering revenue growth Sports Medicine & ENT revenue up 3.9% (3.7% reported), with strong growth from Sports Medicine across Established Markets partially offset by VBP-related headwind in China Advanced Wound Management revenue up 6.5% (underlying and reported), an acceleration over the first half Outlook 1,2 For the full year 2024, underlying revenue growth is now expected to be around 4.5% (previously 5.0% to 6.0%), primarily due to the impact of China headwind. For trading profit margin in 2024, we are now expecting growth of up to 50bps compared to last year's 17.5% (previously at least 18.0%), reflecting the reduced operating leverage from slower revenue growth For 2025, given the updated 2024 outlook and, in particular, uncertainty around ongoing China headwinds, we now expect to expand our trading profit margin significantly to between 19.0% and 20.0%, driven by the continued delivery of the 12-Point Plan improvements Deepak Nath, Chief Executive Officer, sai

Forward-looking Statements

Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate chan

View Full Filing

View this 6-K filing on SEC EDGAR